Alopecia areata occurring during anti-TNF therapy: A national multicenter prospective study

received chemotherapy, with no treatments affecting OS and PFS. The median (interquartile range) follow-up time was 2.9 (1.3 to 4.2) years. Eight patients died during follow-up. Survival analysis revealed a median OS of 6.5 (95% confidence interval (CI), 3.9 to N) years and a median PFS of 1.1 (95% CI, 0.5 to 3) years (Fig 1). The confidence interval for the OS included infinity as an upper bound due to a limited sample size. The 5-year OS rate was 54% (95% CI, 19% to 80%). This study represents an initial step in estimating survival of patients with AJCC stage 4 BSC. The 5-year OS rate of 54% suggests a more favorable prognosis compared with current estimates in the literature of 17.5%, calculated from decades-old case reports of BSCs of all stages. Moreover, comparison of our preliminary data to recent survival analyses of metastatic BCC (median OS [95% CI], 7.3 [1.6 to N] years) and SCC (5-year OS rate [95% CI], 11% [2% to 28%]) supports an intermediate prognosis for BSC relative to the other cancers. Our findings contribute a baseline for further investigation of survival in this uncommon disease and provide clinicians and patients with an estimate of disease prognosis.